What's New

News

Financial Safety and Anosognosia

Partners in FTD Care Winter 2019 Financial supervision early in FTD care is extremely important, particularly when…

Read More >

What to Do About… Anosognosia

Partners in FTD Care Winter 2019 Anosognosia is a lack of awareness of one’s own condition and…

Read More >

Everything Is Just Fine: Anosognosia in Frontotemporal Degeneration

Partners in FTD Care, Winter 2019 Download the full issue (pdf) Caring for people with FTD presents…

Read More >

Spread the Love with AFTD’s With Love Campaign 2019

Valentine’s Day is just around the corner – and with it comes the return of AFTD’s annual…

Read More >

NY Post Highlights Book by Former FTD Care Partner

An article published in the New York Post on January 22 chronicles one woman’s journey as an…

Read More >

AFTD Invests $2.5 Million in ADDF’s Diagnostics Accelerator Program to Develop FTD Biomarkers

Leveraging generous support from our donors, AFTD’s FTD Biomarkers Initiative is expanding. We are investing $2.5MM in…

Read More >

“Sharing Hope” — AFTD’s 2018 Annual Report

AFTD’s 2018 Annual Report documents progress made in the fiscal year commencing July 1, 2017 and ending…

Read More >

FTD and AFTD Now Included in Federal Research Portfolio

AFTD has been added to the International Alzheimer’s and Related Dementias Research Portfolio (IADRP), an online database…

Read More >

Alector Receives Orphan Drug Designation for FTD Therapy

In August, the U.S. Food and Drug Administration (FDA) granted orphan drug designation to Alector for the…

Read More >

Penn FTD Center Scientist Receives AFTD’s First Pilot Grant for Nonpharmacological Research

AFTD has awarded Lauren Massimo, Ph.D., CRNP, the inaugural AFTD Pilot Grant for Nonpharmacological Therapies and Tools….

Read More >